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Summary From 1,211 breast cancers, 15 oestrogen receptor (ER) negative-progesterone receptor (PgR)
positive breast cancers by conventional dextran coated charcoal steroid binding assays in cytosol were
reassessed using Elisa techniques with monoclonal antireceptors antibodies in the cytosolic and nuclear
fractions, and immunocytochemistry on cryostat sections.
Three categories of results were found in this series. Two tumours were false negative ER due to receptor
sites occupancy by hormonal contraceptive treatment. A second group of ten tumours, with high PgR
concentrations and immunoreactive ER, corresponds to non ER-binding forms of receptors. One PgR positive
tumour was found to be devoid of PgR by using monoclonal antiPgR antibodies might contain a progesterone
binding cyst protein. Only two tumours were found to be true ER negative-PgR positive by all methods. This
rare phenotype deserves further study of the regulation of the PgR gene.
A small number of primary or metastatic breast cancer are
oestrogen receptor negative (ER(-)) and progesterone recep-
tor positive (PgR(+)) by conventional radioligand binding
assays. In our series of 1,211 breast tumours 5.78% had this
phenotype. In normal target cells the synthesis of pro-
gesterone receptor is under oestrogen control. In this context,
the existence of ER(-) PgR(+) breast tumours represents an
anomaly.
Several explanations can be put forward: technical
deficiency, occupation of nuclear receptor sites by
endogenous hormones or hormone therapy, existence of
abnormal oestrogen receptors deficient in their hormone bind-
ing domain, or genuine ER(-) PgR(+) tumours.
The use of monoclonal anti ER and PgR antibodies
(immunoassay in cytosolic and nuclear extracts, immuno-
cytochemistry) has allowed to define several subgroups
among these ER(-) PgR(+) tumours.
We have compared the results of the three different tech-
niques (binding, Elisa and immunocytochemistry) on a series
of 15 ER negative-PgR positive breast cancers to stratify this
group into the different categories.
Materials and methods
Tumours
Primary or metastatic breast cancers were selected from our
collection of 1,211 tumours stored in liquid nitrogen after
standard cytosolic steroid receptors analysis by DCC
method. In our experience these storage conditions do not
alter the concentration of receptors and allow their morpho-
logical study by immunocytochemistry.
Stringent criteria were chosen to ascertain the tumours
being ER(-) PgR(+): zero binding sites for ER and more
than 50 fmoles mg-' cytosol protein for PgR.
Assay ofcytosolic and nuclear ER and PgR
Tissue processing Frozen tumours were pulverised in liquid
nitrogen and homogenised at 4'C using an all glass Potter
homogeniser in 1/5 (W/V) TEMG buffer (10 mM Tris, 1.5 mM
EDTA, 5 mM sodium molybdate, 1 mM mercaptoethanol 10%
(V/V) glycerol, HCI pH 7.40). After a 30 min ultracentrifuga-
tion at 105,000 g at 4°C, the supernatant was stored at 40C.
After resuspension in the same buffer, the pellets were rinsed
twice and centrifuged at 800g at 4'C to yield the nuclear
fraction. The supernatants were added to the cytosol frac-
tion.
Nuclear receptors were prepared according to Thorpe et al.
(1987). The nuclear pellet was finally resuspended in 500 lAl of
TEMG buffer without glycerol containing 0.6 M, KCI. Nuclear
receptors were extracted 1 h at 4°C under agitation. The
nuclear extract was finally cleared by an ultracentrifugation
at 105,000g and 4°C for 1 h.
Steroid binding assays in cytosol were previously measured
according to the French National Protocol (Martin et al.,
1981). An intra and interassay standard prepared from calf
uterus containing known amounts of ER and PgR was in-
cluded in each run.
Elisa assays of cytosol ER and PgR were performed as
recommended by the manufacturer's package insert (Abbott
ER-EIA and PgR EIA).
Nuclear receptors were measured on the same samples by
enzyme immunoassay according to Thorpe et al. (1986).
Immunocytochemical detection ofER and PgR (ICC)
Four to six 11 cryostat sections were prepared from a portion
of the tumours stored in liquid nitrogen. The sections were
fixed for 15 min at 4°C in picric acid-paraformaldehyde, in
phosphate buffer saline (PBS) pH 7.40.
ER and PgR staining was obtained by the indirect
immunoperoxydase technique. The ER-ICA kit (Abbott) was
used for ER, and PgR was studied as previously described by
Perrot-Applanat et al. (1987).
A control slide was prepared for each tumour by replacing
the primary antibody by normal serum of the corresponding
species diluted at the same concentration of protein. Positive
controls (MCF-7 cells) were also included in each series. The
semi quantitative evaluation of nuclear staining was based on
the intensity of staining in four classes quoted one for no
staining, two for weak staining, three for intermediate stain-
ing and four for important staining, and on the percentage of
positive epithelial cells.
A minimum of 200 epithelial cells were counted for each
slide. Five classes of per cent positive were used, quoted one
for 0%, two for less than 5% positive cells, three for 5 to
30%, four for 31 to 70% and five over 70% positive cells.
The final score ranging from 1 to 20 was calculated by
multiplying the grades of intensity by the percentage of
positive cells (McClelland et al. (1986)).
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Protein determinations
Protein assays were carried out using the bis-cinchoninic acid
reagent (BCA protein assay, Pierce).
Results
The overall results together with the clinical characteristics of
the patients are listed in Table I. Our series of 15 ER(-)
PgR(+) tumours can be stratified into three categories.
Patient numbers 1 and 2 received hormone therapy (con-
traceptive pills). In this situation, ER binding sites are par-
tially or totally occupied, and hormone receptor complexes
are less extractable by hypotonic buffers in cytosol. This
results in an absence of binding sites by radioligand. How-
ever, some immunoassayable ER is found in tumour cytosol
and nuclear extract. Elevated concentrations of PgR are
observed in both tumours whatever the methods used.
Ten tumours (no. 3 to 12) displayed the same apparent
phenotype, although none of these patients had received
hormonal therapy. In all cases, immunoreactive ER is found
in the nuclear fraction and in cytosol, except for tumour
no. 5 in which the receptor is only present in nuclear extract.
ER was also observed in histologic sections, except for
tumours no. 9 to 12. Breast cancer heterogeneity is a
common feature of these tumours, and might explain that
observation since PgR was present by Elisa techniques and
immunocytochemistry in the same portions of the tumours.
This series of tumours may correspond to non-binding
forms of ER, displaying a relatively low concentration of
immunoreactive receptor in cytosol (16.1 ± 17.7 fmoles mg-'
protein), the major part of it being in the nuclear fraction
(64.2 ± 27.3% of total cellular ER). These tumours have
elevated concentrations of PgR by binding and Elisa tech-
niques, and are also positive by immunocytochemistry with
high scores.
Tumour number 13 had 161 fmoles mg' cytosol protein
of [3H] R5020 binding protein. Using antiprogesterone receptor
monoclonal antibodies, no PgR was detected in cytosol and
nuclear extract. (The limit of sensitivity of the assay given by
the manufacturer was 1 fmolemg-' protein).
The immumocytochemical assay of PgR in the tumour
number 13 was also negative using different monoclonal
antibodies. This result may be ascribed to the presence of a
non-progesterone-receptor binding protein, perhaps the
GCDFP-24 cyst protein described by Pearlman (1977).
Tumours no. 14 and 15 exhibited a particular phenotype:
the oestradiol receptor was absent in the cytosol and nuclear
fractions by both steorid and immunoassay on histological
slides. The progesterone receptor was evidenced by all
available methods. These tumours are to be considered as
'true' ER negative, PgR positive tumours.
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Discussion
The 15 tumours of that study were taken from our library of
1,211 breast cancer, among which 70 (5.78%) are ER
negative-PgR positive by steroid binding assays. This
phenotype has been found to occur in 3% of 1,095 primary
breast cancers by Kiang and Kollander (1987) and in approxi-
matively 6% in another study by Sarrif and Durant (1981).
This group of tumours corresponds to different situations.
The first one, encountered in patients under birth control
pills, or with elevated endogenous hormones, is due to recep-
tor occupancy altering the results of standard ligand binding
assays. A charcoal pretreatment of the cytosol may fre-
quently unmask the oestradiol receptor (72% of the cases in
the study of Sarrif with 18 breast tumours taken from pre or
perimenopausal patients).
The same study shows that this shift in ER status is less
frequent among tumours from patients over 51 years. The
availability of monoclonal antibodies has provided important
tools for further analysis of the ER negative PgR positive
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tumours, because they offer the alternative of antigenic
recognition of the receptors, and are not hampered by the
presence of endogenous hormones. They also allow a mor-
phologic study of ER and PgR in breast tumours sections.
Ten tumours of our series (no. 3 to 12) have immunoreac-
tive ER, without oestrogen binding capacity in the cytosol.
The progesterone receptor is present at relatively high con-
centrations by binding assay (range: 80-1,645 fmolesmg-'
cytosol protein, mean concentration 366.4 fmoles mg-'
cytosol protein). Since PgR was measured in parallel on the
same cytosol preparation, it is improbable that the negative
ER results are due to a technical failure, and intra and
interassay standards of ER and PgR (calf uterine powder
prepared and kept in liquid nitrogen) were also included in
each experiment to validate the assays.
Similar results were obtained on 9/9 tumours by Kiang et
al., and 7/8 tumours were found positive for ER by ICC. Our
proportion of negative tumours by ICC is higher (4/10). The
marked heterogeneity of breast cancer is probably the main
explanation for this discrepancy. Adjacent sections for PgR
immunocytochemistry were all found positive for those
tumours, and positive control slides for ER and PgR were
also included in the experiments.
No hormone therapy was given to those ten patients, 6/10
were menopaused, and one patient was in the follicular phase
(7th day). Precise hormonal status was not available for three
other patients.
A defective oestradiol receptor, with an altered steroid
binding domain could be suspected to be present in these ten
tumours. A similar conclusion has been drawn by Berken-
stam et al. (1989) from their work on the hormonal regula-
tion of ER mRNA in T47DcO and MCF-7 breast cancer
cells. These authors showed that, in T47Dco cells, ER was
absent by steroid binding assay and present at low concentra-
tion by Elisa assay, and that neither down regulation of ER
mRNA by oestradiol, nor up regulation of PgR mRNA was
observed, as it is seen in oestrogen responsive MCF-7 cells.
Finally, the most intriguing tumours are number 14 and
15. They are devoid of ER and express a functionally (at the
binding level) and immunoreactive PgR. This is probably a
very rare situation (2/15 = 13% of ER(-) PgR(+) in our
series, or 0.17% of our overall series).
Two recent works put some insight on the molecular basis
of these rare ER negative PgR positive tumours. Fuqua et al.
(1991) have described a variant of ER devoid of exon 5 of
the hormone binding domain, but able to stimulate PgR
expression in three ER(-) PgR(+) breast tumours. Another
situation was encountered in a T47D cell line with normal
ER and an anomaly of one of the four copies of PgR gene
present in these cells (Savouret et al., 1991). It will thus be of
interest to search for anomalies in the promoter region of the
PgR gene in tumours expressing a true ER(-) PgR(+)
phenotype.
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